A share price of ProKidney Corp [PROK] is currently trading at $0.81, up 0.22%. An important factor to consider is whether the stock is rising or falling in short-term value. The PROK shares have gain 7.79% over the last week, with a monthly amount glided 2.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 10, 2024, and set its price target to $6. BofA Securities downgraded its rating to a Neutral. BTIG Research initiated its recommendation with a Buy and recommended $16 as its price target on July 25, 2023. Jefferies started tracking with a Buy rating for this stock on December 21, 2022, and assigned it a price target of $15. In a note dated November 10, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $13 on this stock.
ProKidney Corp experienced fluctuations in its stock price throughout the past year between $0.46 and $4.44. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. ProKidney Corp [NASDAQ: PROK] shares were valued at $0.81 at the most recent close of the market. An investor can expect a potential return of 476.54% based on the average PROK price forecast.
Analyzing the PROK fundamentals
Gross Profit Margin for this corporation currently stands at 2.72% with Operating Profit Margin at -469.28%, Pretax Profit Margin comes in at -542.68%, and Net Profit Margin reading is -238.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is 0.07 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ProKidney Corp [NASDAQ:PROK] is 10.96. On the other hand, the Quick Ratio is 10.96, and the Cash Ratio is 2.98. Considering the valuation of this stock, the price to sales ratio is 763.29.
Transactions by insiders
Recent insider trading involved Control Empresarial de Capital, Add’l Rep. Persons-see Ex.99-1, that happened on Apr 22 ’25 when 0.39 million shares were purchased. Add’l Rep. Persons-see Ex.99-1, Control Empresarial de Capital completed a deal on Apr 17 ’25 to buy 25000.0 shares. Meanwhile, Add’l Rep. Persons-see Ex.99-1 Control Empresarial de Capital bought 100000.0 shares on Apr 16 ’25.
